709 related articles for article (PubMed ID: 21464183)
1. Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review.
van der Pol RJ; Smits MJ; van Wijk MP; Omari TI; Tabbers MM; Benninga MA
Pediatrics; 2011 May; 127(5):925-35. PubMed ID: 21464183
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of proton pump inhibitors in infantile gastroesophageal reflux disease.
Higginbotham TW
Ann Pharmacother; 2010 Mar; 44(3):572-6. PubMed ID: 20124466
[TBL] [Abstract][Full Text] [Related]
3. Safety and pharmacodynamics of lansoprazole in patients with gastroesophageal reflux disease aged <1 year.
Springer M; Atkinson S; North J; Raanan M
Paediatr Drugs; 2008; 10(4):255-63. PubMed ID: 18590344
[TBL] [Abstract][Full Text] [Related]
4. The use of proton pump inhibitors in children: a comprehensive review.
Gibbons TE; Gold BD
Paediatr Drugs; 2003; 5(1):25-40. PubMed ID: 12513104
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of proton pump inhibitors in the management of pediatric gastroesophageal reflux disease.
Tjon JA; Pe M; Soscia J; Mahant S
Pharmacotherapy; 2013 Sep; 33(9):956-71. PubMed ID: 23712734
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic choices in reflux disease: defining the criteria for selecting a proton pump inhibitor.
Freston JW
Am J Med; 2004 Sep; 117 Suppl 5A():14S-22S. PubMed ID: 15478848
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration.
Hassall E; Kerr W; El-Serag HB
J Pediatr; 2007 Mar; 150(3):262-7, 267.e1. PubMed ID: 17307542
[TBL] [Abstract][Full Text] [Related]
8. Gastroesophageal reflux disease-related symptom recurrence in patients discontinuing proton pump inhibitors for Bravo
Schey R; Alla SP; Midani D; Parkman HP
Rev Gastroenterol Mex; 2017; 82(4):277-286. PubMed ID: 28385467
[TBL] [Abstract][Full Text] [Related]
9. Control of 24-hour intragastric acidity with morning dosing of immediate-release and delayed-release proton pump inhibitors in patients with GERD.
Howden CW; Ballard ED; Koch FK; Gautille TC; Bagin RG
J Clin Gastroenterol; 2009 Apr; 43(4):323-6. PubMed ID: 18758373
[TBL] [Abstract][Full Text] [Related]
10. Lansoprazole: in the management of gastroesophageal reflux disease in children.
Scott LJ
Paediatr Drugs; 2003; 5(1):57-61; discussion 62. PubMed ID: 12513106
[TBL] [Abstract][Full Text] [Related]
11. Alginate therapy is effective treatment for gastroesophageal reflux disease symptoms: a systematic review and meta-analysis.
Leiman DA; Riff BP; Morgan S; Metz DC; Falk GW; French B; Umscheid CA; Lewis JD
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 27671545
[TBL] [Abstract][Full Text] [Related]
12. Adverse effects reported in the use of gastroesophageal reflux disease treatments in children: a 10 years literature review.
Cohen S; Bueno de Mesquita M; Mimouni FB
Br J Clin Pharmacol; 2015 Aug; 80(2):200-8. PubMed ID: 25752807
[TBL] [Abstract][Full Text] [Related]
13. Proton pump inhibitor monotherapy and the risk of cardiovascular events in patients with gastro-esophageal reflux disease: a meta-analysis.
Sun S; Cui Z; Zhou M; Li R; Li H; Zhang S; Ba Y; Cheng G
Neurogastroenterol Motil; 2017 Feb; 29(2):. PubMed ID: 27577963
[TBL] [Abstract][Full Text] [Related]
14. Direct Comparison of the Efficacy and Safety of Vonoprazan Versus Proton-Pump Inhibitors for Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis.
Cheng Y; Liu J; Tan X; Dai Y; Xie C; Li X; Lu Q; Kou F; Jiang H; Li J
Dig Dis Sci; 2021 Jan; 66(1):19-28. PubMed ID: 32095968
[TBL] [Abstract][Full Text] [Related]
15. Alginate therapy is effective treatment for GERD symptoms: a systematic review and meta-analysis.
Leiman DA; Riff BP; Morgan S; Metz DC; Falk GW; French B; Umscheid CA; Lewis JD
Dis Esophagus; 2017 May; 30(5):1-9. PubMed ID: 28375448
[TBL] [Abstract][Full Text] [Related]
16. ANTISECRETORY TREATMENT FOR PEDIATRIC GASTROESOPHAGEAL REFLUX DISEASE - A SYSTEMATIC REVIEW.
Mattos ÂZ; Marchese GM; Fonseca BB; Kupski C; Machado MB
Arq Gastroenterol; 2017 Dec; 54(4):271-280. PubMed ID: 28954042
[TBL] [Abstract][Full Text] [Related]
17. Meta-analyses: does long-term PPI use increase the risk of gastric premalignant lesions?
Eslami L; Nasseri-Moghaddam S
Arch Iran Med; 2013 Aug; 16(8):449-58. PubMed ID: 23906249
[TBL] [Abstract][Full Text] [Related]
18. Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease.
Orenstein SR; Hassall E; Furmaga-Jablonska W; Atkinson S; Raanan M
J Pediatr; 2009 Apr; 154(4):514-520.e4. PubMed ID: 19054529
[TBL] [Abstract][Full Text] [Related]
19. Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review.
Miyazaki H; Igarashi A; Takeuchi T; Teng L; Uda A; Deguchi H; Higuchi K; Tango T
J Gastroenterol Hepatol; 2019 Aug; 34(8):1316-1328. PubMed ID: 30883868
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular Risk of Proton Pump Inhibitors.
Ariel H; Cooke JP
Methodist Debakey Cardiovasc J; 2019; 15(3):214-219. PubMed ID: 31687101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
